

**Table S1: RNA sequence.**

<b>siRNAs</b>	<b>target sequence</b>
si-LACTB	GTGGAATTCGTCATTATGA
si-HuR#1	GACCCAGGATGAGTTACGA
si-HuR#2	GAGCGATCAACACGCTGAA
si-HuR#3	GGTTGCGTTTATCCGGTTT
<b>shRNAs</b>	<b>target sequence</b>
sh-circ#1	ATAGAGCAAGGTTTAGGTTAT
sh-circ#2	GCAAGGTTTAGGTTATGCTGA
<b>LV-RNAs</b>	<b>target sequence</b>
LV-circ	TCAGGATGTAAATATTTGGA

**Table S2: The list of primers and probes.****qPCR primers**

U6	CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT
GAPDH	GGGAGCCAAAAGGGTCATCA	TGATGGCATGGACTGTGGTC
Circ_0104103	CCATAGTAGAGAGAGCTTCAGGATG	ATCAGCATAACCTAACCTTGCTC
LACTB	GCACAGGATCAAGGATGAGGT	TCTGGTTTACATGGTACACGGTT
miR-373-5p	TACTCAAATGGGGGCGCTTTCC	
HuR	GTGAAAATGATGACGGGCTTG	GAGAATGTTCTGAACTGAGAACT

**Table S3. The clinical characters of 30 CRC patients.**

Characteristics	Number of cases	circ0104103 expression		P value <sup>a</sup>
		Low (n=15)	High (n=15)	
<b>Age(year)</b>				
<60	12	7	5	0.456
≥60	18	8	10	
<b>Gender</b>				
Female	10	6	4	0.439
Male	20	9	11	
<b>Tumor invasion depth</b>				
T1-2	18	6	12	<b>0.025</b>
T3-4	12	9	3	
<b>Lymph node metastasis</b>				
N0	21	9	12	0.232
N1+N2	9	6	3	
<b>Distant metastasis</b>				
M0	24	11	14	0.083
M1+M2	6	5	1	
<b>TNM stage</b>				
I+II	17	5	12	<b>0.010</b>
III+III	13	10	3	